CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE

logo

  Avenue De L Hopital 1 – Liege – 4000

  VAT: nan

   www.chuliege.be


Complicit EU Projects



  Within the Horizon 2020 (2014-2020) framework, CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE has received € 538,881.0 for its participation in a total of 5 project(s) with a total cost of € 383,037,145.

Start (YYYYMMDD) Project ID Project Name Themes End (YYYYMMDD) Role EC Contribution Total Cost IL Participation Total Participation CORDIS Link
2015-04-01 633168 BIOCYCLE inflammatory diseases  ·  immunotherapy 2022-12-31 coordinator € 538,881.25 € 5,962,096 1 17 CORDIS ↪
2018-01-01 800858 ICEI neurobiology  ·  data science  ·  software  ·  computational science 2023-09-30 thirdParty € 0.0 € 50,075,048 4 163 CORDIS ↪
2018-04-01 785907 HBP SGA2 artificial intelligence  ·  cognitive neuroscience 2020-03-31 thirdParty € 0.0 € 88,000,000 4 151 CORDIS ↪
2016-04-01 720270 HBP SGA1 computational neuroscience 2018-03-31 thirdParty € 0.0 € 89,000,000 4 138 CORDIS ↪
2020-04-01 945539 HBP SGA3 cognitive neuroscience  ·  databases  ·  revolutions  ·  computational neuroscience  ·  robotics 2023-09-30 thirdParty € 0.0 € 150,000,000 4 162 CORDIS ↪

  Within the Horizon Europe (2021-2027) framework, CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE has received € 1,541,250.0 for its participation in a total of 3 project(s) with a total cost of € 24,064,966.

Start (YYYYMMDD) Project ID Project Name Themes End (YYYYMMDD) Role EC Contribution Total Cost IL Participation Total Participation CORDIS Link
2022-10-01 101070038 TRUMPET data protection  ·  oncology 2025-09-30 participant € 260,000.0 € 4,243,347 1 10 CORDIS ↪
2023-05-01 101095382 FLUTE prostate cancer  ·  innovation management 2026-04-30 participant € 530,000.0 € 6,304,750 1 12 CORDIS ↪
2023-01-01 101096473 LUCIA internet of things  ·  lung cancer  ·  sensors  ·  epigenetics  ·  molecular biology 2026-12-31 participant € 751,250.0 € 13,516,869 4 24 CORDIS ↪

 CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE did not participate in FP7 (2007-2013).